Federal Register / Vol. 60, No. 73 / Monday, April 17, 1995 / Notices 19307

Drug Schedule

4-Bromo-2,5-

dimethoxyphenethylamine

(7392).

I

4-Methyl-2,5-

dimethoxyamphetamine (7395).

I

2,5-Dimethoxyamphetamine (7396) I

3,4-Methylenedioxyamphetamine

(7400).

I

N-Hydroxy-3,4-

methylenedioxyamphetamine

(7402).

I

3,4-

Methylenedioxymethamphetamine (7405).

I

4-Methoxyamphetamine (7411) ..... I

Bufotenine (7433) .......................... I

Diethyltryptamine (7434) ................ I

Dimethyltryptamine (7435) ............. I

Psilocybin (7437) ........................... I

Psilocyn (7438) .............................. I

N-Ethyl-1-phenylcyclohexylamine

(7455).

I

1-(1-Phenylcyclohexy)pyrrolidine

(7458).

I

1-[1-(2-

Thienyl)cyclohexyl]piperidine

(7470).

I

Etorphine (except HCl) (9056) ....... I

Difenoxin (9168) ............................ I

Heroin (9200) ................................. I

Morphine-N-oxide (9307) ............... I

Normorphine (9313) ....................... I

1-Methyl-4-phenyl-4-

propionoxypiperidine (9661).

I

3-Methylfentanyl (9813) ................. I

Alpha-methylfentanyl (9814) .......... I

Beta-hydroxyfentanyl (9830) .......... I

Amphetamine (1100) ..................... II

Methamphetamine (1105) .............. II

Pentobarbital (2270) ...................... II

Secobarbital (2315) ....................... II

Glutethimide (2550) ....................... II

Phencyclidine (7471) ..................... II

1-

Piperidinocyclohexanecarbonitrile (8603).

II

Anileridine (9020) ........................... II

Cocaine (9041) .............................. II

Codeine (9050) .............................. II

Diprenorphine (9058) ..................... II

Benzoylecgonine (9180) ................ II

Ethylmorphine (9190) .................... II

Meperidine (9230) .......................... II

Methadone (9250) ......................... II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ............................ II

Oxymorphone (9652) ..................... II

Alfentanil (9737) ............................. II

Sufentanil (9740) ........................... II

Fentanyl (9801) .............................. II

The firm plans to repackage the

controlled substances in order to supply

pure drugs for drug testing and analysis.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.54 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed

to the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, D.C. 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than May 17,

1995.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1311.42(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1311.42(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: April 7, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 95–9392 Filed 4–14–95; 8:45 am]

BILLING CODE 4410–09–M

Importation of Controlled Substances;

Notice of Application

Pursuant to Section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this Section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under Section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with Section

1311.42 of Title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on February 23, 1995, Stepan

Company, Natural Products Department,

100 W. Hunter Avenue, Maywood, New

Jersey 07607, made application to the

Drug Enforcement Administration to be

registered as an importer of Coca Leaves

(9040), a basic class of controlled

substance in Schedule II.

The firm plans to import the Coca

Leaves to manufacture Cocaine under its

DEA manufacturers registration.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of this basic class of

controlled substance may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.54 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections, or

requests for a hearing may be addressed

to the Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration, United

States Department of Justice,

Washington, DC 20537, Attention: DEA

Federal Register Representative (CCR),

and must be filed no later than (30 days

from publication).

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1311.42 (b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import a basic class of

any controlled substance in Schedule I

or II are and will continue to be required

to demonstrate to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1311.42 (a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: April 7, 1995.

Gene R. Haislip,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 95–9393 Filed 4–14–95; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF LABOR

Office of the Secretary

Women’s Bureau; Commission on

Family and Medical Leave; Public

Hearing

AGENCY: Office of the Secretary, Labor.

ACTION: Notice of public hearing.

SUMMARY: Pursuant to Title III of the

Family Medical Leave Act (FMLA) of

1993 (P.L. 103–3) this is to announce a

hearing on the experience of FMLA for

the Commission which is to take place

on Monday, May 8, 1995. The purpose

of the Commission is to, among other

things, study the effects of existing and
19308 Federal Register / Vol. 60, No. 73 / Monday, April 17, 1995 / Notices

proposed policies relating to family and

medical leave. The Commission has the

practical task of conducting a

comprehensive study of: (a) Existing

and proposed mandatory and voluntary

policies relating to family and

temporary medical leave, including

policies provided by employers not

covered under the Act; (b) the potential

costs, benefits, and impact on

productivity, job creation and business

growth of such policies on employers

and employees; (c) possible differences

in costs, benefits, and impact on

productivity, job creation and business

growth of such policies on employers

based on business type and size; (d) the

impact of family and medical leave

policies on the availability of employee

benefits provided by employers,

including employers not covered under

this Act; (e) alternative and equivalent

State enforcement of Title I with respect

to employees described in section

108(a); (f) methods used by employers to

reduce administrative costs of

implementing family and medical leave

policies; (g) the ability of the employers

to recover, under section 104(c)(2), the

premiums described in such section;

and (h) the impact on employers and

employees of policies that provided

temporary wage replacement during

periods of family and medical leave.

TIME AND PLACE: The hearing will be

held on Monday, May 8, 1995, from 9:30

am until 12:30 pm, at the Dirksen

Federal Office Building, 219 South

Dearborn Street, Chicago, Illinois 60604.

AGENDA: The agenda for the hearing is

as follows: Panel of FMLA supporters,

Panel of FMLA Critics, Panel of Not

Covered Employers and Employees.

STATEMENTS: Interested persons may

submit, in writing, data, information or

views on employer or employee

experiences with FMLA prior to or at

the hearing.

PUBLIC PARTICIPATION: The hearing will

be open to the public. Seating will be

available on a first-come, first-served

basis. Seats will be reserved for the

media. Persons with disabilities should

contact the Commission no later than

April 24, 1995, if special

accommodations are needed.

FOR FURTHER INFORMATION CONTACT:

Susan King, Executive Director,

Commission on Leave, U.S. Department

of Labor, 200 Constitution Avenue NW.,

Room S–3002, Washington, D.C. 20210,

Telephone: (202) 219–4526; Ext. 102.

Signed at Washington, D.C. this 10th day

of April, 1995.

Susan King,

Executive Director, Commission on Leave.

[FR Doc. 95–9327 Filed 4–14–95; 8:45 am]

BILLING CODE 4510–23–M

NATIONAL FOUNDATION ON THE

ARTS AND HUMANITIES

Music Advisory Panel; Meeting

Pursuant to Section 10(a)(2) of the

Federal Advisory Committee Act (Pub.

L. 92–463), as amended, notice is hereby

given that a meeting of the Music

Advisory Panel (Composers Fellowships

Prescreening Sections 2 and 3) to the

National Council on the Arts will meet

on April 27–28, 1995 from 9:00 a.m. to

5:30 p.m. and from May 8–9, 1995 from

9:00 a.m. to 5:30 p.m. Both sections will

meet in room 730, at the Nancy Hanks

Center, 1100 Pennsylvania Avenue, NW,

Washington, DC 20506.

These meetings are for the purpose of

application evaluation, under the

National Foundation on the Arts and the

Humanities Act of 1965, as amended,

including discussion of information

given in confidence to the Agency by

grant applicants. In accordance with the

determination of the Chairman of

February 8, 1994, these sessions will be

closed to the public pursuant to

subsections (c)(4), (6) and 9 (B) of

section 552b of Title 5, United States

Code.

Further information with reference to

this meeting can be obtained from Ms.

Yvonne Sabine, Advisory Committee

Management Office, National

Endowment for the Arts, Washington,

D.C. 20506, or call (202) 682–5788.

Dated: April 12, 1995.

Yvonne M. Sabine,

Director, Council and Panel Operations,

National Endowment for the Arts.

[FR Doc. 95–9438 Filed 4–14–95; 8:45 am]

BILLING CODE 7537–01–M

NUCLEAR REGULATORY

COMMISSION

Advisory Committee on Reactor

Safeguards; Subcommittee Meeting on

Thermal Hydraulic Phenomena; Notice

of Meeting

The ACRS Subcommittee on Thermal

Hydraulic Phenomena will hold a

meeting on May 2, 1995, Room T–2B3,

11545 Rockville Pike, Rockville,

Maryland.

The entire meeting will be open to

public attendance, with the exception of

a portion that may be closed to discuss

Westinghouse Electric Corporation

proprietary information pursuant to [5

U.S.C. 552b(c)(4)].

The agenda for the subject meeting

shall be as follows:

Tuesday, May 2, 1995—8:30 a.m.

until the conclusion of business.

The Subcommittee will continue its

review of the Westinghouse bestestimate thermal hydraulic code, W

COBRA/TRAC. The focus of the meeting

discussion will be on NRR’s review

methodology for best-estimate LOCA

codes vis-a-vis the strictures of the

revised ECCS Rule (10 CFR 50.46). The

purpose of this meeting is to gather

information, analyze relevant issues and

facts, and to formulate proposed

positions and actions, as appropriate,

for deliberation by the full Committee.

Oral statements may be presented by

members of the public with the

concurrence of the Subcommittee

Chairman; written statements will be

accepted and made available to the

Committee. Electronic recordings will

be permitted only during those portions

of the meeting that are open to the

public, and questions may be asked only

by members of the Subcommittee, its

consultants, and staff. Persons desiring

to make oral statements should notify

the cognizant ACRS staff engineer

named below five days prior to the

meeting, if possible, so that appropriate

arrangements can be made.

During the initial portion of the

meeting, the Subcommittee, along with

any of its consultants who may be

present, may exchange preliminary

views regarding matters to be

considered during the balance of the

meeting.

The Subcommittee will then hear

presentations by and hold discussions

with representatives of the NRC staff, its

consultants, and other interested

persons regarding this review.

Further information regarding topics

to be discussed, whether the meeting

has been cancelled or rescheduled, the

scheduling of sessions which are open

to the public, the Chairman’s ruling on

requests for the opportunity to present

oral statements and the time allotted

therefor can be obtained by contacting

the cognizant ACRS staff engineer, Mr.

Paul A. Boehnert (telephone 301/415–

8065) between 7:30 a.m. and 4:15 p.m.

(EDT). Persons planning to attend this

meeting are urged to contact the above

named individual one or two working

days prior to the meeting to be advised

of any potential changes in the proposed

agenda, etc., that may have occurred.